News & Events

Filters

News

Event type

Event region

  • CROI 2019 - GEMINI studies sub-analysis

    Stringent analysis for viral load <40 copies/mL further supports the potency of dolutegravir+lamivudine

    Added on: 15/03/2019

  • CROI 2019—Lamidol

    No change in plasma residual viremia level or in HIV cellular reservoir after 1 year of treatment with DTG+3TC

    Added on: 15/03/2019

  • CROI 2019—DAWNING sub-analysis

    DTG+2 NRTIs vs LPV/r+2 NRTIs (DAWNING): efficacy by baseline NRTI resistance and second-line NRTI use

    Added on: 15/03/2019

  • Glasgow 2018—GEMINI-1 and -2 subgroup analyses

    Subgroup analyses by demographic and baseline characteristics in the GEMINI-1 and GEMINI-2 studies. Effectiveness and safety of DTG + 3TC as a 2-drug regimen in HBV-negative, treatment-naïve adults with viral loads up to 500,000 copies/mL.

    Added on: 28/10/2018

  • Glasgow 2018—Viral decay in A5353 pilot study

    Viral decay in A5353, a pilot study of dolutegravir plus lamivudine vs dolutegravir-based triple therapy. 30% of participants had pretreatment viral loads of 100,000 copies/mL to 500,000 copies/mL.

    Added on: 28/10/2018

  • Glasgow 2018—SWORD-1 and -2: Comparison of viral replication

    Comparison of viral replication for DTG + RPV vs 3-drug current antiretroviral regimen in the SWORD-1 and SWORD-2 studies. Week 100 sub-analysis of transient “blips” in the SWORD-1 and SWORD-2 trials.

    Added on: 28/10/2018

  • Glasgow 2018—SWORD-1 and -2: Viral replication below 50 c/mL

    Viral replication below 50 copies/mL DTG + RPV vs 3-drug current antiretroviral regimen. A Week 48 Snapshot analysis of low-level viremia in the SWORD-1 and SWORD-2 studies.

    Added on: 28/10/2018

PM-GB-DLT-WCNT-190001 - March 2019